• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Ukraine Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Ukraine Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2373003
  • January 2013
  • Region: Ukraine
  • 100 pages
  • Business Monitor International

FEATURED COMPANIES

  • Arterium
  • Company Profiles
  • Gedeon Richter
  • Krka
  • Lek (Novartis/Sandoz)
  • MORE

BMI View:

Foreign and domestic drugmakers in Ukraine will see their operating margins squeezed from 2013 as the Ministry of Health introduces more severe limits on mark-ups. Combined with the likely devaluation of the hryvnia, these factors represent a very large business risk for international drugmakers operating in the country. While Ukraine remains one of Central and Eastern Europe (CEE)'s more promising pharmaceutical markets given its favourable demographics and disease profile, its chronic lack of economic and political stability remains a critical impediment to fulfilling this potential.

Headline Expenditure Projections

- Pharmaceuticals: UAH26.75bn (US$3.35bn) in 2011 to UAH30.79bn (US$3.75bn) in 2012;
+15.1% in local currency terms and +12.1% in US dollar terms. Forecast unchanged from Q412.

- Healthcare: UAH96.98bn (US$12.14bn) in 2011 to UAH109.66bn (US$13.37bn) in 2012;
+13.1% in local currency terms and +10.1% in US dollar terms. Forecast slightly up from Q412 on account of new historical figures.

- Medical devices: UAH6.38bn (US$799mn) in 2011 to UAH7.39bn (US$901mn) in 2012;
+15.8% in local currency terms and +12.8% in US dollar READ MORE >

FEATURED COMPANIES

  • Arterium
  • Company Profiles
  • Gedeon Richter
  • Krka
  • Lek (Novartis/Sandoz)
  • MORE

Executive Summary 5

SWOT Analysis 7

Ukraine Pharmaceutical And Healthcare Industry SWOT 7

Ukraine Political SWOT 8

Ukraine Economic SWOT 9

Ukraine Business Environment SWOT 10

Pharmaceutical Risk/Reward Ratings 11
Table: Emerging Europe - Regional Pharmaceutical Risk/Reward Ratings, Q113 11

Rewards 12

Risks 13

Market Overview 15

Regulatory Regime 16

Recent Regulatory Amendments 18

Pharmaceutical Advertising 20

Intellectual Property Issues 21

Counterfeit Drugs 22

Pricing Regime 23

Recent Pricing Regime Developments 25

Reimbursement Regime 28

Drug Tendering Regime 29

Industry Developments 31

Epidemiology 31
Table: Selected Causes of Death, 2005-2010 (000's) 31
Table: Morbidity by Selected Diseases, 2005-2010 (000's) 32

Public Health Developments 33

Healthcare System 33

Healthcare Funding 34

Healthcare System Reform 34

Health Insurance Developments 35

Healthcare Provision 36
Table: Number of Outpatient Facilities, 1995-2010 36

Research and Development (R&D) 37

Clinical Trials 39

Medical Devices 39

Industry Forecast Scenario 41

Pharmaceutical Market Forecast 41
Table: Pharmaceutical Sales, Historical Data and Forecasts 43

Healthcare Market Forecast 44
Table: Healthcare Expenditure Trends, Historical Data and Forecasts 48
Table: Government Healthcare Expenditure Trends, Historical Data and Forecasts 48
Table: Private Healthcare Expenditure Trends, Historical Data and Forecasts 49

Key Growth Factors - Macroeconomic 50

Prescription Drug Market Forecast 53
Table: Ukraine Prescription Drug Market Indicators, Historical Data and Forecasts 54

Patented Drug Market Forecast 55
Table: Patented Drug Market Indicators, Historical Data and Forecasts 56

Generic Drug Market Forecast 57
Table: Generics Drug Market Indicators, Historical Data and Forecasts 58

OTC Medicine Market Forecast 59
Table: OTC Medicine Market Indicators, Historical Data and Forecasts 60

Pharmaceutical Trade Forecast 61
Table: Pharmaceutical Trade Data And Forecasts (US$mn) 63
Table: Pharmaceutical Trade Data And Forecasts (UAHmn) 63

Medical Device Market Forecast 64
Table: Medical Device Market Indicators, Historical Data and Forecasts 65

Other Healthcare Data 66

Key Risks to Forecasts 67

Competitive Landscape 68

Pharmaceutical Industry 68
Table: Retail Pharmacy Sales Value & Volume, 2004-2010 (Million) 69
Table: Retail Pharmacy Sales Value by Leading Company, 2007-2010 (UAH Million) 69
Table: Retail Pharmacy Sales Value & Volume by Origin, 2010 (Million) 70
Table: Retail Pharmacy Sales Volume by Leading Company, 2010 (Million) 70

Domestic Pharmaceutical Sector 72

Foreign Pharmaceutical Sector 75
Table: Association of International Manufacturers (AIPM) Ukraine Members, 2011 75

Recent Company Activities 77

Pharmaceutical Wholesale 78

Pharmaceutical Retail 79

Company Profiles 82

Arterium 82

Gedeon Richter 84

Krka 86

Lek (Novartis/Sandoz) 88
Table: Ukraine's Population By Age Group, 1990-2020 ('000) 91
Table: Ukraine's Population By Age Group, 1990-2020 (% of total) 92
Table: Ukraine's Key Population Ratios, 1990-2020 93
Table: Ukraine's Rural And Urban Population, 1990-2020 93

Glossary 94

BMI Methodology 96

How We Generate Our Pharmaceutical Industry Forecasts 96

Pharmaceuticals Risk/Reward Ratings Methodology 97

Ratings Overview 97
Table: Pharmaceutical Risk/Reward Ratings Indicators 98

Weighting 99
Table: Weighting Of Components 99

Sources 99

Company Profiles
Arterium
Gedeon Richter
Krka
Lek (Novartis/Sandoz)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos